Canakinumab is a human monoclonal antibody that targets IL-1β approved for the treatment of CAPS and is undergoing clinical trials for chronic obstructive pulmonary disease (COPD) and gout. This evidence concerns the gene IL1B and chronic obstructive pulmonary disease.